U.S. Patent Office Reaffirms PharmaStem Patent.WAYNE, Pa. -- PharmaStem Therapeutics, Inc. announced today that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has issued a ruling confirming the validity of PharmaStem Therapeutics, Inc.'s pioneering patent about the Isolation and Preservation of Fetal and Neonatal Hematopoietic hematopoietic /he·ma·to·poi·et·ic/ (-poi-et´ik) 1. pertaining to hematopoiesis. 2. an agent that promotes hematopoiesis. hematopoietic 1. pertaining to or affecting the formation of blood cells. Stem and Progenitor Cells of the Blood and Methods of Therapeutic Use. The Patent Office has issued a "Notice of Intent to Issue a Re-examination Certificate" after re-evaluating PharmaStem's U.S. Patent No. 5,192,553, thus terminating the reexamination re·ex·am·ine also re-ex·am·ine tr.v. re·ex·am·ined, re·ex·am·in·ing, re·ex·am·ines 1. To examine again or anew; review. 2. Law To question (a witness) again after cross-examination. proceeding. In its Decision the U.S. Patent Office stated that "the Prior art rejections of record have been withdrawn ... The primary references in these rejections Douay, Koike, Ende, Knudtzon, do not teach or suggest that cryopreserved fetal stem cells would obtain hematopoietic reconstitution of a human..." "I am gratified grat·i·fy tr.v. grat·i·fied, grat·i·fy·ing, grat·i·fies 1. To please or satisfy: His achievement gratified his father. See Synonyms at please. 2. by this Decision by which the Patent Office confirms again the pioneering contributions of PharmaStem in the development of umbilical cord blood umbilical cord blood Transplantation A source of primitive and stem cells that can be used to reconstitute BM destroyed by aplastic anemia or by RT or chemotherapy for CA, lymphoproliferative malignancies. See Bone marrow transplantation, Stem cell therapy. preservation and its therapeutic use," said Nicholas Didier, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and President of PharmaStem. PharmaStem is the successor to Biocyte Corporation, and the pioneer in the development of umbilical cord blood preservation and its therapeutic use. Umbilical cord and placental blood are rich in stem cells that can reconstitute human blood and immune systems. The Company provided the roadmap for the creation of today's rapidly growing field of cord blood storage for therapeutic use. To learn more about PharmaStem Therapeutics, its patent portfolio and its licensed cord blood banks, please visit www.pharmastem.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion